These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 22184057)
21. Effects of mineralocorticoid receptor blockade on glucocorticoid-induced renal injury in adrenalectomized rats. Rafiq K; Nakano D; Ihara G; Hitomi H; Fujisawa Y; Ohashi N; Kobori H; Nagai Y; Kiyomoto H; Kohno M; Nishiyama A J Hypertens; 2011 Feb; 29(2):290-8. PubMed ID: 21243738 [TBL] [Abstract][Full Text] [Related]
22. Interactions between aldosterone and connective tissue growth factor in vascular and renal damage in spontaneously hypertensive rats. de las Heras N; Ruiz-Ortega M; Miana M; Rupérez M; Sanz-Rosa D; Aragoncillo P; Mezzano S; Cachofeiro V; Egido J; Lahera V J Hypertens; 2007 Mar; 25(3):629-38. PubMed ID: 17278980 [TBL] [Abstract][Full Text] [Related]
23. Mineralocorticoid Receptor Blockade Improves Insulin Sensitivity in the Rat Heart and a Possible Molecular Mechanism. Wang M; Li Y; Zhou K; Zhang G; Wang Y; Liu T; Zhang Y; Guo A; An Y Cell Physiol Biochem; 2016; 39(3):860-70. PubMed ID: 27497962 [TBL] [Abstract][Full Text] [Related]
32. Eplerenone mimics features of the alternative activation in macrophages obtained from patients with heart failure and healthy volunteers. Łabuzek K; Liber S; Bułdak Ł; Krupej-Kędzierska J; Machnik G; Bobrzyk M; Okopień B Eur J Pharmacol; 2014 Mar; 726():96-108. PubMed ID: 24486397 [TBL] [Abstract][Full Text] [Related]
34. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury. Luther JM; Luo P; Wang Z; Cohen SE; Kim HS; Fogo AB; Brown NJ Kidney Int; 2012 Sep; 82(6):643-51. PubMed ID: 22622494 [TBL] [Abstract][Full Text] [Related]
35. Non-genomic effects of spironolactone and eplerenone in cardiomyocytes of neonatal Wistar rats: do they evoke cardioprotective pathways? Hermidorff MM; Faria Gde O; Amâncio Gde C; de Assis LV; Isoldi MC Biochem Cell Biol; 2015 Feb; 93(1):83-93. PubMed ID: 25488178 [TBL] [Abstract][Full Text] [Related]
36. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone. Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748 [TBL] [Abstract][Full Text] [Related]
37. Mineralocorticoid receptor throughout the vessel: a key to vascular dysfunction in obesity. Pojoga LH; Baudrand R; Adler GK Eur Heart J; 2013 Dec; 34(45):3475-7. PubMed ID: 23666249 [No Abstract] [Full Text] [Related]
38. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone. Hu X; Li S; McMahon EG; Lala DS; Rudolph AE Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407 [TBL] [Abstract][Full Text] [Related]